Holen Sie sich die Stockscreener-App
873.68
0.06%
0.56
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$873.12
Offen:
$880.62
24-Stunden-Volumen:
3.76M
Relative Volume:
1.06
Marktkapitalisierung:
$830.35B
Einnahmen:
$45.04B
Nettoeinkommen (Verlust:
$10.59B
KGV:
74.61
EPS:
11.71
Netto-Cashflow:
$414.30M
1W Leistung:
+3.48%
1M Leistung:
+17.69%
6M Leistung:
-8.22%
1J Leistung:
+17.13%
1-Tages-Spanne:
$873.43
$894.40
1-Wochen-Bereich:
$851.36
$894.40
52-Wochen-Spanne:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
3 Magnificent Growth Stocks to Buy Right Now - The Motley Fool
Major Stock Movement: Lilly Endowment Inc Sells Shares of Eli Lilly & Co - TipRanks
Eli Lilly Has Exclusivity Over Weight Loss Drug, FDA Says - Law360
Lilly Endowment sells $12.9 million in Eli Lilly stock - Investing.com
Is Eli Lilly and Company (LLY) the Best Non-Tech Stock to Buy Now for Long Term? - Insider Monkey
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile - Reuters
Eli Lilly (LLY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Major Shareholder Makes a Big Move with Eli Lilly & Co Stock! - TipRanks
Lilly Endowment Inc sells $8.77 million in Eli Lilly shares By Investing.com - Investing.com UK
ELI LILLY AND COMPANY (LLY) - MSN
Eli Lilly's Options Frenzy: What You Need to Know - Benzinga
The Alzheimer's Drug Discovery Foundation Announces Daniel M. Skovronsky, MD, PhD, of Eli Lilly & Company, as Recipient of Prestigious 2025 Melvin R. Goodes Prize - citybiz
Eli Lilly and Company (LLY): Among the Best Long-Term Stocks to Buy According to Ken Fisher - Insider Monkey
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile By Reuters - Investing.com
Eli Lilly’s (NYSE:LLY) Future Takes Aim at Big Problems in Plain Sight - TipRanks
Eli Lilly wants to use its weight loss drug windfall to fight Alzheimer's and hearing loss - Yahoo Finance
Eli Lilly obesity drug trial participants losing ‘too much weight,’ STAT reports - TipRanks
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall - CNBC
From pills to new uses, here's what Eli Lilly’s top scientist sees as the future of weight loss drugs - CNBC
Argus Adjusts Price Target on Eli Lilly to $1,000 From $980 -February 20, 2025 at 08:35 am EST - Marketscreener.com
Eli Lilly Files For Mixed Shelf Size Not DisclosedSEC Filing -February 19, 2025 at 05:46 pm EST - Marketscreener.com
Eli Lilly & Co. (LLY) Files Mixed Shelf - StreetInsider.com
Lilly, Novo Fight Weight Loss Drug Compounders Over Shortage - Bloomberg Law
ELI LILLY & Co SEC 10-K Report - TradingView
SEC Form 10-K filed by Eli Lilly and Company - Quantisnow
Fat, not muscle: drugmakers in race for next weight-loss breakthrough -February 19, 2025 at 10:06 am EST - Marketscreener.com
Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production - PharmaVoice
Fat, not muscle: drugmakers in race for next weight-loss breakthrough -February 19, 2025 at 06:08 am EST - Marketscreener.com
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District - Indianapolis Business Journal
APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses - BioWorld Online
TD Cowen 45th Annual Health Care Conference | Eli Lilly and Company - Investors | Eli Lilly and Company
Lilly to participate in TD Cowen's 45th Annual Health Care Conference - Investors | Eli Lilly and Company
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading Down 3.1%Here's What Happened - MarketBeat
Chronic Lower Back Pain Market Expected to rise, 2034 | Eli Lilly - openPR
Eli Lilly & Co: Promising Growth Driven by Innovative Pipeline and Market-Leading Weight-Loss Treatments - TipRanks
TigerOak Management L.L.C. Takes $522,000 Position in Eli Lilly and Company (NYSE:LLY) - MarketBeat
Why Eli Lilly and Company (LLY) Is the Best Drug Stock to Buy Now - Insider Monkey
Eli Lilly Reports Record Q4 2024 Revenue of $13.53B, Fueled by Mounjaro, Zepbound, and Oncology Growth - BSA bureau
Lebanon planning board to review designs for Lilly’s $4.5B foundry at LEAP District - Inside INdiana Business
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake - The Motley Fool
1,149 Shares in Eli Lilly and Company (NYSE:LLY) Acquired by CFC Planning Co LLC - MarketBeat
Eli Lilly Full-Year Earnings Meet Expectations Amid GLP-1 Inventory Challenges – market - HPBL
Major Shareholder Makes a Significant Move with Eli Lilly & Co Stock! - TipRanks
Top Stock Reports for Apple, Eli Lilly & Shopify - Yahoo Finance
Lilly Endowment sells $31.18 million in Eli Lilly stock - Investing.com
Innovating beyond boundaries: Sarah O’Keeffe’s career in making medicine - Irish Examiner
1,080 Shares in Eli Lilly and Company (NYSE:LLY) Bought by Kentucky Trust Co - MarketBeat
Eli Lilly leads M&A bond charge in US IG market - GlobalCapital
Is Eli Lilly and Company (LLY) the Best Large Cap Dividend Growth Stock to Buy Now? - Insider Monkey
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):